Clinical Trials

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Number: NCT02266745
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Phosplatin Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Number: NCT02465060
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can

Number: NCT02484404
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

Number: NCT02713269
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Number: NCT02946996
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Medical University of South Carolina
Sponsor Trial Information
Trial Location(s) and Contact(s)
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Number: NCT02949284
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rutgers, The State University of New Jersey|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Number: NCT02960022
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Astellas Pharma Global Development, Inc.|Pfizer|Astellas Pharma Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Number: NCT03009981
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Alliance Foundation Trials, LLC.|Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Number: NCT03016741
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 4
Sponsor(s): Northwestern University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Number: NCT03047135
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|AstraZeneca
Sponsor Trial Information
Trial Location(s) and Contact(s)
68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

Number: NCT03113617
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Andrei Iagaru|Stanford University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Number: NCT03150810
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): BeiGene|Myriad Genetics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Number: NCT03170960
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s)
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Number: NCT03333616
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Dana-Farber Cancer Institute|Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s)
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Number: NCT03419234
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group
Sponsor Trial Information
Trial Location(s) and Contact(s)
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Number: NCT03436654
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute
Sponsor Trial Information
Trial Location(s) and Contact(s)
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

Number: NCT03541928
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): The Methodist Hospital Research Institute
Sponsor Trial Information
Trial Location(s) and Contact(s)
Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Number: NCT03570619
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Michigan Rogel Cancer Center|Memorial Sloan Kettering Cancer Center|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer

Number: NCT03581500
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Number: NCT03582475
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Jonsson Comprehensive Cancer Center|Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

Number: NCT03637543
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Beth Israel Deaconess Medical Center|Bristol-Myers Squibb|Dana-Farber Cancer Institute
Sponsor Trial Information
Trial Location(s) and Contact(s)
Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer

Number: NCT03654638
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Number: NCT03678025
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Southwest Oncology Group|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone

Number: NCT03707184
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Utah
Sponsor Trial Information
Trial Location(s) and Contact(s)
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Number: NCT03753243
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Mark Garzotto, MD|Merck Sharp & Dohme Corp.|Astellas Pharma Inc|Portland VA Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Number: NCT03767244
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Number: NCT03777982
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Dana-Farber Cancer Institute|Janssen Scientific Affairs, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
The Effect of Deep Versus Moderate Muscle Relaxants in Men During and After Robotic Surgery for Prostate Cancer

Number: NCT03808077
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Memorial Sloan Kettering Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

Number: NCT03821792
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer

Number: NCT03824275
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2|Phase 3
Sponsor(s): Columbia University
Sponsor Trial Information
Trial Location(s) and Contact(s)
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy

Number: NCT03824652
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Stephen Freedland|California Walnut Commission|Cedars-Sinai Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer

Number: NCT03833921
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Martha Mims|Baylor College of Medicine
Sponsor Trial Information
Trial Location(s) and Contact(s)
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Number: NCT03860987
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Number: NCT03899987
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Roswell Park Cancer Institute|National Cancer Institute (NCI)|AIM ImmunoTech Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Number: NCT03910660
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): BioXcel Therapeutics Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy

Number: NCT03949517
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Andrei Iagaru|General Electric|Stanford University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

Number: NCT03964337
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Duke University|Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s)
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

Number: NCT03976843
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

Number: NCT03987386
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer

Number: NCT04011410
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Andrew C. James, MD|University of Kentucky
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

Number: NCT04019327
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Memorial Sloan Kettering Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Number: NCT04030559
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, Davis|National Cancer Institute (NCI)|Janssen, LP
Sponsor Trial Information
Trial Location(s) and Contact(s)
Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer

Number: NCT04037254
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

Number: NCT04037358
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor Trial Information
Trial Location(s) and Contact(s)
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Number: NCT04126070
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Xiao X. Wei|Bristol-Myers Squibb|Dana-Farber Cancer Institute
Sponsor Trial Information
Trial Location(s) and Contact(s)
An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

Number: NCT04134208
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 4
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

Number: NCT04134260
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Number: NCT04136353
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Bayer|Cancer Trials Ireland|Canadian Cancer Trials Group|Memorial Sloan Kettering Cancer Center|Prostate Cancer Clinical Trials Consortium
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)

Number: NCT04157088
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer

Number: NCT04167969
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Memorial Sloan Kettering Cancer Center|Elucida Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer

Number: NCT04179968
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Dana Mathews|University of Texas Southwestern Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

Number: NCT04194554
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): University of Michigan Rogel Cancer Center|Janssen Scientific Affairs, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Number: NCT04246671
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Bavarian Nordic
Sponsor Trial Information
Trial Location(s) and Contact(s)
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

Number: NCT04253483
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rutgers, The State University of New Jersey|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Abiraterone Acetate, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Number: NCT04262154
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Memorial Sloan Kettering Cancer Center|Genentech, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Number: NCT04267887
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): OHSU Knight Cancer Institute|Janssen Scientific Affairs, LLC|Oregon Health and Science University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer

Number: NCT04301414
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Matthew Dallos|Bristol-Myers Squibb|Ferring Pharmaceuticals|Columbia University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)

Number: NCT04349501
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, San Diego
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Number: NCT04383210
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Elevation Oncology
Sponsor Trial Information
Trial Location(s) and Contact(s)
18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer

Number: NCT04390880
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): VA Greater Los Angeles Healthcare System
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

Number: NCT04402151
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Weill Medical College of Cornell University|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications

Number: NCT04423029
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Dragonfly Therapeutics|Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s)
EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer

Number: NCT04465500
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Virginia
Sponsor Trial Information
Trial Location(s) and Contact(s)
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

Number: NCT04493853
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): AstraZeneca
Sponsor Trial Information
Trial Location(s) and Contact(s)
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Number: NCT04513717
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Number: NCT04530552
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Number: NCT04550494
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

Number: NCT04600336
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Number: NCT04606446
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Number: NCT04644068
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): AstraZeneca
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Number: NCT04666129
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Myovant Sciences GmbH
Sponsor Trial Information
Trial Location(s) and Contact(s)
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

Number: NCT04700332
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Hoag Memorial Hospital Presbyterian
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Number: NCT04709276
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Andrew J. Armstrong, MD|Bristol-Myers Squibb|Duke University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer

Number: NCT04725903
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s): Emory University|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Number: NCT04734730
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): City of Hope Medical Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

Number: NCT04743934
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Andrew McDonald|University of Alabama at Birmingham
Sponsor Trial Information
Trial Location(s) and Contact(s)
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer

Number: NCT04777071
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington
Sponsor Trial Information
Trial Location(s) and Contact(s)
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer

Number: NCT04842890
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): The New York Proton Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

Number: NCT04879940
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Number: NCT04898634
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Number: NCT04947254
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Insulin Resistance and Androgen Deprivation Therapy

Number: NCT04995978
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): St. Louis University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Pioglitazone and Insulin Resistance in ADT

Number: NCT05098327
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): State University of New York at Buffalo
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

Number: NCT05100472
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Memorial Sloan Kettering Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

Number: NCT05133440
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Memorial Sloan Kettering Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Targeted Alpha Therapy With 225Actinium-PSMA-I&T of Castration-resISTant Prostate Cancer (TATCIST).

Number: NCT05219500
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Excel Diagnostics and Nuclear Oncology Center
Sponsor Trial Information
Trial Location(s) and Contact(s)

Total: 86 Clinical Trials





PHEN,Inc. © 2022 All rights reserved